May 22 (Reuters) - Australian hospital group Healthscope said on Tuesday it would not provide due diligence access for takeover offers worth more than $3 billion each from Brookfield Asset Management and BGH Capital, stating both offers undervalue the company.
In a separate announcement, the company said it had received a number of suitors for its Asian Pathology business and had initiated a sale process.
The company also said it expected core earnings from hospital operations to be in the range of A$340 million to A$345 million ($257.89 million-$261.68 million) for fiscal 2018, compared to core earnings of A$359.4 million in 2017. ($1 = 1.3184 Australian dollars) (Reporting by Ambar Warrick in Bengaluru)
Our Standards: The Thomson Reuters Trust Principles.